Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Extensive-stage small-cell lung cancer, drawn from the whole corpus: 52 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
No biomarker identifies the minority who gain long-term benefit from immunotherapy; PD-L1 and mutational burden do not work in small-cell disease.
Tarlatamab needs inpatient monitoring for cytokine release syndrome, which limits access outside specialist centres.
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Immune-related side effects · Toxicity compare · Survivorship planner.
Whether the transcription factor subtypes can direct treatment is unproven.
Brain metastases remain common and prophylactic irradiation trades cognition for a benefit that is uncertain with MRI surveillance.
Also on OnCo: Atlas of advanced disease · How cancer spreads: the metastasis stages.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 28 changes by month →When this page itself was last checked or edited.
Maintenance with atezolizumab in ES-SCLC after first-line induction; 29 May 2026
ES-SCLC after platinum-based chemotherapy; 29 May 2026
Met the primary overall survival endpoint at the pre-specified interim analysis (Amgen, 8 September 2026); progression-free survival and response rate also improved; figures not yet disclosed.
European Commission approval for ES-SCLC
First-line maintenance with atezolizumab in ES-SCLC (full approval)